All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that cannot be cured with surgery. Participants must have previously received treatment with two cancer drugs: atezolizumab and bevacizumab. Doctors want to find out if keeping patients on an immunotherapy drip (atezolizumab) while adding targeted cancer tablets (either lenvatinib or sorafenib) works better than taking the tablets alone. Standard treatment usually switches patients to the tablets by themselves once first treatments stop working. Participants will be placed by chance into one of two groups. One group receives the combination of the drip and the tablets, while the other takes only the tablets. Researchers will closely measure how long the treatment keeps the cancer under control, overall survival times, quality of life, and any side effects. Taking part helps researchers discover better, more effective treatment options for people facing advanced liver cancer.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
F. Hoffmann-La Roche AG
Enrolment target
270
Start
19 Feb 2024

What is this study about?

Hepatocellular carcinoma is the most common form of primary liver cancer. When this cancer is discovered at a later stage, or has spread, surgery to cut away the tumour is often not possible. Doctors call this 'unresectable' cancer. In recent years, a combination of an immunotherapy medicine called atezolizumab and a targeted drug called bevacizumab has become a common first choice of treatment. However, liver cancer can eventually start growing again, meaning patients need new treatment options.

Currently, when the first treatment stops working, standard practice often involves switching to targeted daily medicines called sorafenib or lenvatinib. These medicines work by blocking signals that cancer cells need to grow and build blood supplies. This study is testing a new approach: continuing the atezolizumab immunotherapy drip alongside either sorafenib or lenvatinib tablets, to see if the combination works better than taking the tablets alone.

Because this is a Phase 3 study, it is one of the final stages of testing before a treatment approach can become widely approved on the NHS. Researchers want to see whether continuing immunotherapy helps patients live longer, slows down tumour growth, and helps maintain their day-to-day quality of life. The findings could change how doctors around the world treat advanced liver cancer in the future.

Key takeaways

  • Phase 3 study testing whether combining immunotherapy and targeted tablets is better than tablets alone.
  • Designed for adults with liver cancer that cannot be removed by surgery and has grown after previous treatment.
  • Participants are randomly assigned to receive either the combination therapy or single-drug tablet therapy.
  • Involves regular hospital check-ups, scans, and blood tests to monitor tumour size and overall health.
  • Participation is completely voluntary, and you can withdraw at any point without losing your usual standard of care.

Who may be eligible?

This trial is open to men and women aged 18 and older who have been diagnosed with advanced primary liver cancer that cannot be removed by an operation. To be considered, you must have already had treatment with atezolizumab and bevacizumab, and your medical team has found that your cancer is no longer responding to that initial therapy.

Because your safety is the top priority, you will need to meet general health requirements to ensure your body can cope with the study medicines. Your liver and kidneys must still be working reasonably well, and you should be well enough to carry out daily tasks without needing constant assistance.

You may not be eligible if you have certain other medical conditions, severe liver failure, or active autoimmune conditions that could make immunotherapy unsafe. Your hospital doctor will review your full medical history and perform safety tests before you can take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed with primary liver cancer (hepatocellular carcinoma).
  3. My cancer cannot be completely removed with surgery.
  4. I have already received treatment with atezolizumab and bevacizumab.
  5. I am well enough to walk around and manage my own personal care.
Answer every question to see your result.

What does participation involve?

If you join the trial, a computer will assign you by chance (randomly) to one of two groups. One group will take targeted medicine alone (either sorafenib tablets or lenvatinib capsules taken by mouth each day). The other group will take those same daily tablets but will also receive atezolizumab as an intravenous drip into a vein, usually given once every few weeks at the hospital.

Taking part involves regular visits to the hospital clinic. During these visits, doctors will check your blood, measure your vital signs, ask about any symptoms or side effects, and have you complete short surveys about your quality of life. You will also have regular CT or MRI scans to track how the tumour is responding. You will continue the trial treatment for as long as your cancer stays stable and the side effects are manageable, or until you and your doctor decide it is best to stop.

Potential risks and benefits

A potential benefit of joining this study is that you may receive a treatment combination that keeps your cancer from growing for longer, while receiving very close health monitoring from a dedicated cancer team. However, there is no guarantee the combination will work better than the standard tablets alone. All cancer treatments carry risks of side effects; the tablets can cause tiredness, diarrhoea, skin rashes, or high blood pressure, while the drip can trigger inflammation in healthy organs. You are entirely free to leave the trial at any time, for any reason, and your regular NHS medical care will continue without being affected.

Locations (12)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Finland
  • —
    Unverified
    Spain
  • —
    Unverified
    Belgium
  • —
    Unverified
    France
  • —
    Unverified
    Austria
  • —
    Unverified
    Greece
  • —
    Unverified
    Italy
  • —
    Unverified
    Bulgaria
  • —
    Unverified
    Estonia
  • —
    Unverified
    Germany
  • —
    Unverified
    Slovenia
  • —
    Unverified
    Croatia

Common questions

What is the main purpose of this study?

The study aims to see if combining an immunotherapy drip with targeted daily tablets helps people with advanced liver cancer live longer and healthier lives compared to taking the tablets alone.

Can I choose which treatment group I am placed in?

No. A computer randomly decides which group you join. This process is like flipping a coin and ensures that the trial results are fair and scientifically accurate.

How often will I need to visit the hospital?

Visits are typically every few weeks for scans, blood tests, check-ups, and drip treatments. Your trial team will give you a detailed schedule of visits.

What happens if the treatment causes bad side effects?

Your safety comes first. The doctors can adjust your medicine dose, pause treatment, or give you medicines to help relieve side effects. If needed, you can stop the trial treatment altogether.

Do I have to pay for the trial medicines?

No. The study medications and any trial-specific tests are provided free of charge, and some travel expenses may also be reimbursed.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WI…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.